{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:09:29Z","timestamp":1784200169596,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Azienda Unit\u00e0 Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jaut.2019.01.002","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T19:48:40Z","timestamp":1547063320000},"page":"113-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8622-0439","authenticated-orcid":false,"given":"Stefania","family":"Croci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bonacini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Muratore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Boiardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cavazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cimino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Belloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mati","family":"Fridkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Parmeggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miri","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2019.01.002_bib1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrrheum.2012.97","article-title":"Clinical features of polymyalgia rheumatica and giant cell arteritis","volume":"8","author":"Salvarani","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2019.01.002_bib2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(08)61077-6","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"372","author":"Salvarani","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2019.01.002_bib3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2013.161","article-title":"Immune mechanisms in medium and large-vessel vasculitis","volume":"9","author":"Weyand","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2019.01.002_bib4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra011913","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"347","author":"Salvarani","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2019.01.002_bib5","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia rheumatica and giant cell arteritis: a systematic review","volume":"315","author":"Buttgereit","year":"2016","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.jaut.2019.01.002_bib6","doi-asserted-by":"crossref","first-page":"e3524","DOI":"10.1097\/MD.0000000000003524","article-title":"Flares in biopsy-proven giant cell arteritis in northern Italy: characteristics and predictors in a long-term follow-up study","volume":"95","author":"Restuccia","year":"2016","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.jaut.2019.01.002_bib7","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MD.0000000000000033","article-title":"Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients","volume":"93","author":"Alba","year":"2014","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.jaut.2019.01.002_bib8","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/MD.0b013e31821c4fad","article-title":"Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain","volume":"90","author":"Martinez-Lado","year":"2011","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.jaut.2019.01.002_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jaut.2016.10.002","article-title":"Long-term remission in biopsy proven giant cell arteritis: a retrospective cohort study","volume":"77","author":"Restuccia","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.01.002_bib10","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.01.002_bib11","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2019.01.002_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2019.01.002_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10409238909082550","article-title":"Tuftsin: its chemistry, biology, and clinical potential","volume":"24","author":"Fridkin","year":"1989","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.jaut.2019.01.002_bib14","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1128\/IAI.01168-12","article-title":"Microbial modulation of host immunity with the small molecule phosphorylcholine","volume":"81","author":"Clark","year":"2013","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jaut.2019.01.002_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2015.03.001","article-title":"Successful modulation of murine lupus nephritis with tuftsin-phosphorylcholine","volume":"59","author":"Bashi","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.01.002_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/cei.12745","article-title":"Novel therapeutic compound tuftsin-phosphorylcholine attenuates collagen-induced arthritis","volume":"184","author":"Bashi","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2019.01.002_bib17","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/cei.13137","article-title":"Tuftsin-phosphorylcholine (TPC) equally effective to methylprednisolone in ameliorating lupus nephritis in a mice model","volume":"193","author":"Shemer","year":"2018","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2019.01.002_bib18","doi-asserted-by":"crossref","first-page":"e0200615","DOI":"10.1371\/journal.pone.0200615","article-title":"Helminths-based bi-functional molecule, tuftsin-phosphorylcholine (TPC), ameliorates an established murine arthritis","volume":"13","author":"Blank","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2019.01.002_bib19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jaut.2014.11.001","article-title":"Phosphorylcholine-tuftsin compound prevents development of dextransulfate-sodium-salt induced murine colitis: implications for the treatment of human inflammatory bowel disease","volume":"56","author":"Ben-Ami","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.01.002_bib20","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.1780330810","article-title":"The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis","volume":"33","author":"Hunder","year":"1990","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.01.002_bib21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/annrheumdis-2012-202883","article-title":"Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis","volume":"73","author":"Corbera-Bellalta","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.01.002_bib22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/rheumatology\/kex334","article-title":"Increased expression of interleukin-22 in patients with giant cell arteritis","volume":"57","author":"Zerbini","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2019.01.002_bib23","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1136\/annrheumdis-2015-207846","article-title":"MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis","volume":"75","author":"Croci","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.01.002_bib24","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.autrev.2017.05.014","article-title":"Recent advances in our understanding of giant cell arteritis pathogenesis","volume":"16","author":"Samson","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2019.01.002_bib25","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.autrev.2017.05.004","article-title":"New insights into the pathogenesis of giant cell arteritis","volume":"16","author":"Ciccia","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2019.01.002_bib26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jbspin.2016.07.005","article-title":"Pro-inflammatory and anti-inflammatory T cells in giant cell arteritis","volume":"84","author":"Watanabe","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jaut.2019.01.002_bib27","doi-asserted-by":"crossref","first-page":"ii51","DOI":"10.1093\/rheumatology\/kex423","article-title":"Pathogenesis of giant-cell arteritis: how targeted therapies are influencing our understanding of the mechanisms involved","volume":"57","author":"Terrades-Garcia","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2019.01.002_bib28","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1136\/annrheumdis-2018-213488","article-title":"Interleukin 12 and interleukin 23 play key pathogenic roles in inflammatory and proliferative pathways in giant cell arteritis","volume":"77","author":"Conway","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.01.002_bib29","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/jnc.12404","article-title":"Tuftsin signals through its receptor neuropilin-1 via the transforming growth factor beta pathway","volume":"127","author":"Nissen","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jaut.2019.01.002_bib30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1073\/pnas.012074399","article-title":"Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis","volume":"99","author":"Oh","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.jaut.2019.01.002_bib31","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/cvr\/cvv229","article-title":"Neuropilins 1 and 2 mediate neointimal hyperplasia and re-endothelialization following arterial injury","volume":"108","author":"Pellet-Many","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.jaut.2019.01.002_bib32","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1042\/BJ20100580","article-title":"Neuropilin-1 mediates PDGF stimulation of vascular smooth muscle cell migration and signalling via p130Cas","volume":"435","author":"Pellet-Many","year":"2011","journal-title":"Biochem. J."},{"key":"10.1016\/j.jaut.2019.01.002_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3322","article-title":"The microvascular niche instructs T cells in large vessel vasculitis via the VEGF-Jagged1-Notch pathway","volume":"9","author":"Wen","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jaut.2019.01.002_bib34","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1136\/ard.2007.070805","article-title":"Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis","volume":"67","author":"Lozano","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.01.002_bib35","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/CIRCRESAHA.108.185777","article-title":"Toll-like receptors 4 and 5 induce distinct types of vasculitis","volume":"104","author":"Deng","year":"2009","journal-title":"Circ. Res."},{"key":"10.1016\/j.jaut.2019.01.002_bib36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/187153012799278893","article-title":"Immunomodulatory properties of ES-62, a phosphorylcholine-containing glycoprotein secreted by Acanthocheilonema viteae","volume":"12","author":"Al-Riyami","year":"2012","journal-title":"Endocr. Metab. Immune Disord. - Drug Targets"},{"key":"10.1016\/j.jaut.2019.01.002_bib37","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/modpathol.2017.10","article-title":"Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients","volume":"30","author":"Maleszewski","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.jaut.2019.01.002_bib38","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1172\/JCI119477","article-title":"Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras","volume":"99","author":"Brack","year":"1997","journal-title":"J. Clin. Invest."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841118305493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841118305493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:21:11Z","timestamp":1760257271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841118305493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":38,"alternative-id":["S0896841118305493"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2019.01.002","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2019.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}